At the end of 2016 a paper was published in Lancet claiming a perfect Ebola vaccine trial, with nobody who received the vaccine getting diagnosed with Ebola after a suitable waiting period. David read this carefully and concluded that the trial was designed in a terrible fashion and actually is more compatible with the vaccine causing side effects that could be confused with Ebola, and not compatible with a reduction in Ebola cases. It may, in other words, increase the risk of Ebola-like disease. He wrote a letter to Lancet that was rejected, but recently had a peer reviewed paper published in the American Journal of Immunology, which forms the basis of this episode.
The Lancet article can be found here:http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)32621-6/fulltext
David’s peer reviewed article is here: http://thescipub.com/abstract/10.3844/ofsp.11329